Zynerba closes enrolment in Phase II trials of ZYN002 for osteoarthritis and epilepsy

US-based specialty pharmaceutical firm Zynerba Pharmaceuticals has closed enrolment in the Phase II STAR 1 and Phase II STOP clinical trials of ZYN002 for the treatment of osteoarthritis and epilepsy.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news